Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 9/2016

01-09-2016 | Neurological Update

Some recent advances in multiple sclerosis

Authors: Claire McCarthy, John Thorpe

Published in: Journal of Neurology | Issue 9/2016

Login to get access

Abstract

In this article, we review some of the key advances in multiple sclerosis (MS) over the last 3 years. Significant progress has been made in understanding the genetics and pathogenesis of MS. The classification of MS phenotypes has been revised and the landscape of therapeutics is rapidly evolving. We provide a practical summary of the main developments for the practising neurologist.
Literature
1.
Rocca MA, Messina R, Filippi M (2013) Multiple sclerosis imaging: recent advances. J Neurol 260:929–935CrossRefPubMed
2.
Belbasis L, Bellow V, Evangelou E, Ioannidis JP, Tzoulaki I (2015) Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 14:263–273CrossRefPubMed
3.
Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545–558CrossRefPubMed
4.
Jersild C, Svejgaard A, Fog T (1972) HL-A antigens and multiple sclerosis. Lancet 299:1240–1241CrossRef
5.
6.
International Multiple Sclerosis Genetics Consortium (IMSGC) (2013) Advances in genetics of MS: Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45:1353–1360CrossRef
7.
Farh KKH, Marson A, Zhu J et al (2015) Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518:337–343CrossRefPubMed
8.
International Multiple Sclerosis Genetics Consortium (IMSGC) (2013) Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet 92:854–865CrossRef
9.
Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–88108CrossRefPubMed
10.
Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B et al (2012) Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 367:115CrossRefPubMed
11.
Brickshawana A, Hinson SR, Romero MF et al (2014) Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol 13:795–806CrossRefPubMedPubMedCentral
12.
Nerrant E, Salsac C, Charif M et al (2014) Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler 20:1699–1703CrossRefPubMed
13.
Hemmer B (2015) Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies—conflicting results? Mult Scler 21:537–539CrossRefPubMed
14.
Filippi M, Rocca MA, Lassmann H (2014) KIR4.1: another misleading expectation in multiple sclerosis? Lancet Neurol 13:753–755CrossRefPubMed
15.
16.
Calabresi PA, Kieseier BC, Arnold DL et al (2014) Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 13:657–665CrossRefPubMed
17.
Hunt D, Kavanagh D, Drummond I, Weller B, Bellamy C, Overell J, Evans S, Jackson A, Chandran S (2014) Thrombotic microangiopathy associated with interferon beta. N Engl J Med 370:1270–1271CrossRefPubMedPubMedCentral
18.
19.
Fox RJ, Miller DH, Phillips JT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087–1097CrossRefPubMed
20.
Gold R, Kappos L, Arnold DL et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098–1107CrossRefPubMed
21.
22.
McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2015) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. doi:10.​1136/​jnnp-2015-311100. (Published Online First: 22 October 2015)
23.
24.
O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76:1858–1865CrossRefPubMed
25.
Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F (2014) Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 261:1170–1177CrossRefPubMed
26.
Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP et al (2014) MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 82:1491–1498CrossRefPubMedPubMedCentral
27.
28.
Cohen JA, Coles AJ, Arnold DL et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828CrossRefPubMed
29.
Coles AJ, Fox E, Vladic A et al (2012) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78:1069–1078CrossRefPubMed
30.
Wade DT, Young CA, Chaudhuri KR, Davidson DLW (2002) A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and l-phenylalanine (the “Cari Loder regime”) in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:246–249CrossRefPubMedPubMedCentral
31.
Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B (2010) The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomised placebo-controlled trial. Mult Scler 16:964–969CrossRefPubMed
32.
Zamboni P, Galeotti R, Menegatti E et al (2009) A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg 50:1348–1358CrossRefPubMed
33.
34.
Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832–2838CrossRefPubMed
35.
Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 61:504–513CrossRefPubMed
36.
Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ (2011) A randomized trial of high-dose vitamin D2 in relapsing remitting multiple sclerosis. Neurology 77:1611–1618CrossRefPubMed
37.
Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P (2011) Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 40:627–639CrossRefPubMed
38.
Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H (2012) Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012:452541PubMedPubMedCentral
39.
Soilu-Hanninen M, Aivo J, Lindstrom BM et al (2012) A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83:565–571CrossRefPubMed
40.
Aivo J, Lindsrom BM, Soilu-Hanninen M (2012) A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Mult Scler Int 2012:802796PubMedPubMedCentral
41.
Røsjø E, Steffensen LH, Jørgensen L, Lindstrøm JC, Šaltytė Benth J, Michelsen AE, Aukrust P, Ueland T, Kampman MT, Torkildsen Ø, Holmøy T (2015) Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. J Neurol 262:2713–2721CrossRefPubMed
42.
Steffensen LH, Jørgensen L, Straume B, Mellgren SI, Kampman MT (2011) Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol 258:1624–1631CrossRefPubMedPubMedCentral
43.
Pihl-Jensen G, Frederiksen JL (2015) 25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis. J Neurol 262:1646–1654CrossRefPubMed
44.
Malik MT, Healy BC, Benson LA, Kivisakk P, Musallam A, Weiner HL, Chitnis T (2014) Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology 82:2173–2179CrossRefPubMedPubMedCentral
45.
Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, Gout O, Lyon-Caen O, Tourbah A (2015) High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mul Scler Relat Disord 4:159–169CrossRef
46.
Chataway J, Schuerer N, Alsanousi A et al (2014) Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383:2213–2221CrossRefPubMed
47.
48.
Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E et al (2015) Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. NEJM 373:1418–1428CrossRefPubMed
49.
Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R (2006) Regulatory CD56 super(bright) natural killer cells mediate immunomodulatory effects of IL-2R α-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci 103:5941–5946CrossRefPubMedPubMedCentral
50.
Metadata
Title
Some recent advances in multiple sclerosis
Authors
Claire McCarthy
John Thorpe
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 9/2016
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-016-8124-1

Other articles of this Issue 9/2016

Journal of Neurology 9/2016 Go to the issue

Original Communication

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

Letter to the Editors

CSF1R-related leukoencephalopathy mimicking primary progressive multiple sclerosis

Journal club

The consequences of valproate exposure in utero

Letter to the Editors

Charles Bonnet syndrome successfully treated with levetiracetam

Original Communication

Altered striatal circuits underlie characteristic personality traits in Parkinson’s disease

Original Communication

CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt–Jakob disease suspected cases with inconclusive 14-3-3 result